Filtros de búsqueda

Lista de obras de Louis Preston Garrison

A Flexible Approach To Evidentiary Standards For Comparative Effectiveness Research ⬇️

artículo científico publicado el 1 de octubre de 2010

A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]

artículo científico publicado en 2018

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

artículo científico publicado en 2018

A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine

scientific article published on 01 October 2019

A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications

article

An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]

scientific article published on 01 February 2018

Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis

artículo científico publicado en 2007

Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A

artículo científico publicado en 2020

Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status ⬇️

artículo científico publicado el 17 de junio de 2013

Association between Health-Related Quality of Life and Body Mass After Adjustable Gastric Banding: A Nonlinear Approach ⬇️

artículo científico publicado el 9 de julio de 2013

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support

artículo científico publicado en 2020

Authors' reply to Curto and Garattini: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers"

artículo científico publicado en 2014

Can and should value-based pricing be applied to molecular diagnostics?

artículo científico publicado en 2013

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

scientific article published on 11 March 2019

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

artículo científico publicado en 2007

Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers

artículo científico publicado en 2014

Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

artículo científico publicado en 2018

Do cancer treatments have option value? Real-world evidence from metastatic melanoma

artículo científico publicado en 2019

Economic incentives for evidence generation: promoting an efficient path to personalized medicine

artículo científico publicado en 2013

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis

artículo científico publicado en 2009

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

artículo científico publicado en 2009

Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.

artículo científico publicado en 2009

How Comparative Effectiveness Research Can Help Advance ‘Personalized Medicine’ In Cancer Treatment ⬇️

artículo científico publicado el 1 de diciembre de 2011

How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma

artículo científico publicado en 2019

Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)

artículo científico publicado en 2015

Insurance coverage for genomic tests

artículo científico publicado en 2018

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework

scientific article published on 13 June 2016

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

scientific article published on 11 March 2010

Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals

scientific article published on 01 October 2009

Paying for personalized care: Cancer biomarkers and comparative effectiveness ⬇️

artículo científico publicado el 6 de marzo de 2012

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force

artículo científico publicado en 2013

Private sector risk-sharing agreements in the United States: trends, barriers, and prospects

artículo científico publicado en 2015

Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy

artículo científico publicado en 2019

Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].

artículo científico publicado en 2018

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study

scientific article published on 02 November 2018

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

artículo científico publicado en 2015

The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems

scientific article published on 22 July 2019

The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer

artículo científico publicado en 2009

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer

artículo científico publicado en 2008

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis

artículo científico publicado en 2017

Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests

artículo científico publicado en 2006

Understanding the economic value of molecular diagnostic tests: case studies and lessons learned

artículo científico publicado en 2013

Using Cost-Effectiveness Analysis to Support Research and Development Portfolio Prioritization for Product Innovations in Measles Vaccination ⬇️

artículo científico publicado el 1 de julio de 2011

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

artículo científico publicado en 2007

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda